EXPLORE!

Drug to Reduce Bone Marrow Suppression due to Chemotherapy Approved

  825 Views

eMediNexus    14 February 2021

Trilaciclib became the first drug in its class to be approved by the U.S. Food and Drug Administration for reducing the incidence of chemotherapy-induced bone marrow suppression in patients being given chemotherapy for extensive-stage small cell lung cancer.

The drug may provide protection to the bone marrow cells against damage from chemotherapy by inhibition of cyclin-dependent kinase 4/6.

Three randomized, double-blind, placebo-controlled trials conducted in patients with extensive-stage small cell lung cancer randomized a total of 245 patients to either trilaciclib or a placebo prior to chemotherapy. Patients given trilaciclib were found to have reduced odds of having severe neutropenia in comparison with patients receiving a placebo. Among the patients who had severe neutropenia, those on trilaciclib treatment had it for a shorter duration on average, compared to patients who received a placebo… (FDA, February 12, 2021)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.